SPACs could grease the wheels for European biotechs looking for U.S. listing

With over 60 healthcare-focused SPACs coming to market in the past 15 months, LSP is hoping to differentiate its blank check vehicle by specifically targeting European biopharmas and, in the process, set a precedent for how to shorten the journey European biotechs take to a U.S. listing. 

LSP-sponsored European Biotech Acquisition Corp. (NASDAQ:EBACU) raised $120 million in a bumped up IPO on March 15, becoming the first SPAC to list from a major life sciences-focused European VC...